AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02491502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echopulse
Description: HIFU Under ultrasound guidance
Study NCT04905875 — intervention group
Intervention type: PROCEDURE
Intervention: Prone Position
Description: Every center will prescribe PP in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
Study NCT01264159 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lung impedence-guided therapy
Study NCT01264159 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual treatment of patients with developing acute heart failure
Study NCT04455178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: spironolactone 20mg once daily, up-titrated to 40mg once daily at 4-week or 8-week visit
Study NCT04455178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indapamide
Description: indapamide 1.5mg once daily, up-titrated to 3mg once daily at 4-week or 8-week visit
Study NCT00812422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexibuprofen
Description: one dose of Dexibuprofen 2.5 or 5 mg/kg
Study NCT00812422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexibuprofen
Description: one dose of Dexibuprofen 3.5 or 7 mg/kg
Study NCT00812422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: one dose of Ibuprofen 5 or 10 mg/kg
Study NCT00869986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dirucotide
Description: 500mg, intravenous, every 6 months for 15 months
Study NCT04386356 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orotracheal intubation with either Macintosh laryngoscope versus Airtraq video laryngoscope
Description: Tracheal intubation will be performed by first year anaesthesia trainee using either Macintosh laryngoscope or Airtraq video laryngoscope according to the randomization sequence supervised by an experienced anaesthesiologist and data recorded by an independent observer on one group of patients.
Study NCT02411526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX003 (Risperidone-SABER®)
Description: ZX003 administered as a SC injection
Study NCT00869986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: intravenous, once every six months for 15 months
Study NCT02978924 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tsDCS
Description: 20 min of treatment applied at the thoracic level (active electrode) with reference placed on the right shoulder
Study NCT02978924 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tsDCS
Description: 20 min of treatment applied at the thoracic level (active electrode) with reference placed on the right shoulder
Study NCT01576094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone
Description: Before surgery, patients received milrinone (MR) (milrinone lactate 1 mg/ml). Intravenous continuous infusion of the study drug through a separate central line started intraoperatively and was increased step-wise at predefined time points: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission providing the patient was in stable haemodynamic condition; dose 3, starting after 2 hours of stability with dose 2, and maintained up to 48 hours IND infusion started. Accordingly, patients randomised to MR received 0.5 , 0.75 and 1 microg/kg per min
Study NCT01576094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Description: Before surgery patients received levosimendan (levosimendan 2.5 mg/ml). Intravenous continuous infusion of the study drug through a separate central line started intraoperatively and was increased step-wise at predefined time points: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission providing the patient was in stable haemodynamic condition; dose 3, starting after 2 hours of stability with dose 2, and maintained up to 48 hours IND infusion started. Accordingly, patients randomised to LEVO received 0.1 , 0.15 and 0.2 microg/kg per min, for doses 1, 2 and 3, respectively.
Study NCT01435226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-5885
Description: Drug: GS-5885 tablet~GS-5885 tablet, 90 mg, QD
Study NCT01435226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-9451
Description: Drug: GS-9451 tablet~GS-9451 tablet, 200 mg QD
Study NCT00724932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: After the last dose of rocuronium has been administered, participants will receive, according to the randomization, a single bolus dose of 4.0 mg.kg-1 sugammadex at 1-2 PTC.
Study NCT00332917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pardoprunox
Description: 12-42 mg
Study NCT01499199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: 50mg Once Daily
Study NCT02662894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 160mg + Rosuvastatin 20mg
Description: 1 tablet, oral, a day
Study NCT02662894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 320mg + Rosuvastatin 20mg
Description: 1 tablet, oral, a day
Study NCT02662894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diovan® 160mg + Crestor® 20mg
Description: Take together 1 tablet of Diovan (160mg) plus 1 tablet of Crestor (20mg), oral, once daily.
Study NCT02662894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diovan® 320mg + Crestor® 20mg
Description: Take together 1 tablet of Diovan (320mg) plus 1 tablet of Crestor (20mg), oral, once daily.
Study NCT05631210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Privacy agreements with pictograms
Description: The intervention consisted of a modified privacy agreement talking about health data. Instead of presenting all of that information through text, the investigators added pictograms that summarized the key points at the beginning.
Study NCT04065113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Middle Meningeal Artery Embolization with polyvinyl alcohol particles (PVA)
Description: Seal off blood supply to the middle meningeal artery to prevent growth of subdural hematoma
Study NCT04065113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drainage of Subdural Hematoma
Description: Drainage of subdural hematoma via burrhole or craniotomy
Study NCT04065113 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drainage of Subdural Hematoma
Description: Drainage of subdural hematoma via burrhole or craniotomy
Study NCT00573482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REDE
Description: The intervention group received the education in REDE techniques.~The intervention in this study comprised four components:~* Four group education sessions to introduce the REDE principles of eating;~* Approximately 10 new lower energy-dense foods were introduced in the employee cafeteria daily at lunchtime;~* Food labels for all foods sold in the employee cafeteria at lunch time, which provided the energy density, calories, and macronutrient content of the prepared cafeteria foods. Prior to the intervention almost no foods had food labels.~* Price reductions for lower energy density items. Both groups were exposed to the food labels and the new lower ED foods, but only the intervention group received the education sessions about how to take advantage of the new labels and cafeteria foods and only they were eligible for the price reductions.
Study NCT00573482 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: The control group received no REDE intervention at all. Both groups were exposed to the food labels and the new lower ED foods, but the control group did not receive the education sessions.
Study NCT02317965 — intervention group
Intervention type: OTHER
Intervention: Maternal Blood Draw
Description: Maternal Blood Draw
Study NCT03069313 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: Vitamin B12 2500 micrograms sublingually per day over the course of 90 days (+/- 10 days)
Study NCT04152694 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ceftaroline levels in CRRT
Description: Levels of ceftaroline measured in patients receiving CRRT
Study NCT01435226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tegobuvir
Description: tegobuvir 30 mg BID
Study NCT01435226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to match tegobuvir
Description: tegobuvir placebo BID
Study NCT01435226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to match RBV
Description: Ribovirin placebo BID
Study NCT01435226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin (Copegus®) BID (1000 mg for subjects weighing \< 75 kg and 1200 mg for subjects weighing ≥ 75 kg) divided BID
Study NCT04320979 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: internal mammary nodal irradiation
Description: chest wall and supraclavicular +-axillary plus internal mammary nodal irradiation (50 Gy in 25 fractions or 43.5Gy in 15 fractions).
Study NCT02411526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperdal Consta
Description: Risperdal Consta administered as a IM injection
Study NCT02411526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Risperidone
Description: Oral Risperidone given to ensure adequate therapeutic plasma concentrations from Risperdal Consta
Study NCT00208494 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Replacement
Description: Total hip replacement
Study NCT00208494 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip replacement
Description: Total hip replacement
Study NCT01733901 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RSD
Description: Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celcius Thermocool,Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About six to nine ablations at 10 W for 1 min each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
Study NCT01733901 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PCI
Description: Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat the stenotic coronary arteries of the heart found in CHD. During PCI, a cardiologist feeds a deflated balloon or other device on a catheter from the inguinal femoral artery or radial artery up through blood vessels until they reach the site of blockage in the heart. X-ray imaging is used to guide the catheter threading. At the blockage, the balloon is inflated to open the artery, allowing blood to flow. A stent is often placed at the site of blockage to permanently open the artery.
Study NCT01733901 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat the stenotic coronary arteries of the heart found in CHD. During PCI, a cardiologist feeds a deflated balloon or other device on a catheter from the inguinal femoral artery or radial artery up through blood vessels until they reach the site of blockage in the heart. X-ray imaging is used to guide the catheter threading. At the blockage, the balloon is inflated to open the artery, allowing blood to flow. A stent is often placed at the site of blockage to permanently open the artery.
Study NCT05529290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen Trometamol + Thiocolchicoside
Description: Dexketoprofen Trometamol + Thiocolchicoside (25mg + 4mg) is a NSAID. It was given to the patients twice a day.
Study NCT05529290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen Trometamol + Paracetamol
Description: Dexketoprofen Trometamol + Paracetamol (25mg + 300mg) is a NSAID. It was given to the patients twice a day.
Study NCT05529290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen Trometamol (25mg)
Description: Dexketoprofen Trometamol (25mg) is a NSAID. It was given to the patients twice a day.
Study NCT05529290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Paracetamol (500 mg) is a mild analgesic and antipyretic. It was given to the patients to take only if needed as max. dose 2000mg.
Study NCT01252342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 10 U intramyometrial oxytocin bolus immediately after cesarian delivery, and an infusion of 20 U/L of oxytocin at 500ml/hr.
Study NCT01252342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 10U intramyometrial normal saline bolus immediately after cesarian delivery, and an infusion of 20U/L of oxytocin at 500ml/hr.
Study NCT02321618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BP measurement & pharmacy
Description: Blood pressure monitoring by barber, blood pressure medication management by pharmacist, role model posters encouraging program participation
Study NCT02321618 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: BP educational materials
Description: Exposure to hypertension educational materials
Study NCT03011580 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fultium-D3
Description: Fultium-D3 (oral cholecalciferol or vitamin D3) will be given to participants in the immediate supplementation arm at a dose of 9,600 IU/day for 8 weeks at V2. At V3, all participants will be given a supply of Fultium-D3 at a dose of 3,200 IU/day.
Study NCT03011580 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules of placebo will be given daily to participants in the delayed supplementation arm for 8 weeks at V2.
Study NCT00966303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation with diaphragmatic muscle training
Description: Stretching and aerobic exercises and respiratory muscle training with a Threshold ® device, with load of 40% of the maximal inspiratory pressure (MIP), two times a week during one hour.
Study NCT01991938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-5584
Study NCT05164679 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multimodal training (MMT)
Description: Supervised multimodal exercise training (MMT) performed 1-2 hours weekly for 19 weeks
Study NCT04613102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVCN583601 (3% Cannabidiol cream)
Description: Topical application twice daily for 4 weeks (phase 2) and for 8 weeks (phase 3).
Study NCT01551953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai chi
Description: 12 week tai chi class
Study NCT03018912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep VS
Description: During check in patients are instructed to complete the Sleep VS survey packet only. The Sleep VS survey packet will take approximately 4 minutes to complete. The packet includes the subjective Sleep VS and additional sleep questionnaires, such as ESS, FOSQ-10, ISI, and sleep-wake pattern questions.~The subjective Sleep VS is composed of the following 2 questions:~1. How many days a week are you satisfied with your sleep?~2. How many days a week is sleepiness a problem?
Study NCT05962918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perinal massage
Description: Perineal massage was administered to all pregnant women in the experimental group during both the labor and resting phases between contractions. The participants received an average of 5-10 minutes of perineal massage two, four and four to six times at the latent (0-3-cm cervical dilation), active (4-7-cm cervical dilation) and transition (8-10-cm cervical dilation) phases of labor, respectively. These women continued to receive perineal massage at every push throughout the second stage of labor. The researcher midwife gently widened the perineal muscles by making stretching movements with her fingers. Perineal massage was applied using all three of the from one edge to the other, U shape and pressure massage techniques. The researcher gently applied a rhythmic U pressure with both fingers, moving them on the vagina downwards about 3 to 9 o'clock. Each pressure movement was maintained laterally for 1-2 minutes towards the rectum.
Study NCT00607568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: atomoxetine 40mg per day or placebo~For Phase I, subjects will be assigned to atomoxetine or placebo for 4 days. Subjects will then have a 4-15 day washout period and will be crossed over to the alternative treatment for Phase II.
Study NCT00607568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atomoxetine
Description: atomoxetine 40mg per day or placebo~For Phase I, subjects will be assigned to atomoxetine or placebo for 4 days. Subjects will then have a 4-15 day washout period and will be crossed over to the alternative treatment for Phase II.
Study NCT01551953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-body breathing
Description: 12 week breathing class
Study NCT01551953 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: 12 week education class
Study NCT04009213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LiquiBand FIX8®
Description: An n-butyl-2-cyanoacrylate adhesive monomer and D\&C Violet #2 dye
Study NCT04009213 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AbsorbaTack™
Description: An absorbable synthetic polyester copolymer derived from lactic and glycolic acid and is dyed with D\&C Violet No. 2.
Study NCT02591004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magesium sulphate
Description: \*Experimental: Group A: Magesium sulphate 4 gm intravenous (I.V) loading dose over 30 mins \& 1 gm/ hour maintenance dose for 24 hours, or till labor occurs ( whichever occurs first)
Study NCT02591004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: \*Active Comparator: Group B Nifedipine wil be given in a loading dose of 40 mg in the 1st hour (10mg will be given every 15 min), then a maintenance dose of 60mg /24 hours, divided in 3 doses
Study NCT02591004 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Doppler on fetal middle cerebral artery
Description: both group A and group B: ultrasound doppler to measure the mean pulsility index (PI) and resistance index (PI) of the middle cerebral artery in the fetus twice, once before giving them the drug, and the other after 4 hours of starting the loading dose.
Study NCT02591004 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Doppler on fetal middle cerebral artery
Description: both group A and group B: ultrasound doppler to measure the mean pulsility index (PI) and resistance index (PI) of the middle cerebral artery in the fetus twice, once before giving them the drug, and the other after 4 hours of starting the loading dose.
Study NCT03489993 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ang II and Ang-(1-7)
Description: Measured in plasma and urine using radioimmunoassays.
Study NCT03489993 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FGF23 and klotho
Description: Measured using ELISA's.
Study NCT03264794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib Tab （CTTQ），First medication；Gefitinib Tab （CTTQ），From the 8th day of trial
Description: Gefitinib Tab （CTTQ），First medication,250mg；
Study NCT03264794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib tablets (Yi Ruisha），First medication
Description: Gefitinib tablets (Yi Ruisha），First medication,250mg；
Study NCT03264794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib Tab 250 MG（CTTQ），From the 8th day of trial.
Description: From the 8th day of the experiment, two groups of subjects were treated with Gefitinib（CTTQ）
Study NCT03264794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib Tab 250 MG（CTTQ），From the 8th day of trial.
Description: From the 8th day of the experiment, two groups of subjects were treated with Gefitinib（CTTQ）
Study NCT03179579 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC with neoadjuvant chemotherapy
Description: HIPEC 3 times +NACT 2 cycles +CRS +HIPEC 3 times+ ACT 4-6 cycles
Study NCT03179579 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Systemic chemotherapy
Description: NACT 3 cycles +CRS +ACT 4-6 cycles
Study NCT04320979 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: no internal mammary nodal irradiation
Description: chest wall and supraclavicular+-axillary nodal irradiation (50 Gy in 25 fractions or 43.5Gy in 15 fractions).
Study NCT01474902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Lovenox- Enoxaparin; Sanofi-Aventis Canada Inc.